TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02495207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
Study: NCT03480230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound 121564
Description: Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
Study: NCT00028587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT02911701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT01522547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Study: NCT02911701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT02027493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reiferon R
Description: subcutaneous injection of 100 μg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reiferon R
Description: subcutaneous injection of 100 μg/m2
Study: NCT02786537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)
Description: Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)
Description: Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
Study: NCT02027493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 15 mg/kg daily on two divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 15 mg/kg daily on two divided doses
Study: NCT00429962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal ranibizumab
Description: intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab & photodynamic therapy
Description: intraocular injection photodynamic treatment (LASER) after intravenous injection
Study: NCT01604941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602
Description: 50 mg/kg/day orally twice daily for 24 weeks
Study: NCT02184936

Intervention type: OTHER
Intervention: standard of care
Study: NCT01120340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine
Description: mesalamine: 1.6 g/die for ten days/month until 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 pills/day for ten days/month until 24 months
Study: NCT01344590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Standard saline procedure will be utilized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol 70% pharmaceutical grade
Description: 70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
Study: NCT04194801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg
Description: Phase Ib: participants received 400 mg Fisogatinib (BLU-554) once daily (QD), in combination with 1200mg fixed dose Sugemalimab (CS1001) once every 3 weeks (Q3W). Every 21 days (3 weeks) will be considered as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
Description: Phase Ib: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
Description: Phase II: participants received 600 mg Fisogatinib (BLU-554) QD, in combination with 1200mg fixed dose Sugemalimab (CS1001) Q3W. Every 21 days (3 weeks) will be considered as one cycle.
Study: NCT01793558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Description: In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
Study: NCT02518945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin or Farxiga is a SGLT-2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Victoza(Liraglutide) is a GLP-1 agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Victoza(Liraglutide) is a GLP-1 agent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin placebo
Description: Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
Study: NCT04056585

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided axillary plexus block
Description: Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided axillary plexus block
Description: Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression maneuver
Description: Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
Study: NCT03740295

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil and epigallocatechin gallate
Description: 600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose
Study: NCT03307577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-101 Cream
Description: Topical cream containing investigational drug at a concentration of 1%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Topical cream containing no drug (i.e., placebo)
Study: NCT02531620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiatry Assessment
Description: Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Care
Description: Usual care for your disease process
Study: NCT01995227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax
Description: Personalized anti-cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRCL
Description: Personalized anti-cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: ID injections IV infusion
Study: NCT02793245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire on their main characteristics : age, gender, height, weight, smoking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified pulmonary function test
Study: NCT02817867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + TMS
Description: Association between tDCS and TMS.
Study: NCT02919540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care approach
Description: skin to skin contact between stable preterm infants and their naked mother's chest
Study: NCT05513677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M4D
Description: Coated catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT02341846

Intervention type: OTHER
Intervention: Qualitative interviews

Intervention type: OTHER
Intervention: Qualitative interviews

Intervention type: OTHER
Intervention: Qualitative interviews
Study: NCT02070458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT00443391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Open label study, subjects will take up to 80mg daily for 24 months.
Study: NCT02982161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Dosing frequency: four times daily, Mode of administration: oral
Study: NCT02786537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBR/GZR (elbasvir/grazoprevir)
Description: Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBR/GZR (elbasvir/grazoprevir)
Description: Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg pills (1-3 pills, 1-2 times per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg pills (1-3 pills, 1-2 times per day)
Study: NCT01692587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein restrictive diet
Description: To begin a reduced protein diet
Study: NCT01540734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: Marketed formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental formulation
Study: NCT04508985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temporarily holding the RAAS inhibitor [intervention]
Description: Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.

Intervention type: OTHER
Group type: OTHER
Intervention: RAAS inhibitor [continued standard of care]
Description: No intervention, Continuation RAAS inhibitor \[continued standard of care\].
Study: NCT00712049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 40 mg
Study: NCT02786537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg pills (1-3 pills, 1-2 times per day)
Study: NCT03738124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Thoracic Stent Graft System
Description: The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
Study: NCT02598713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspiration Marker
Description: Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
Study: NCT05624372

Intervention type: DIAGNOSTIC_TEST
Intervention: hearing and cognitive assessment
Description: psychiatric assessment, hearing assessment and brief cognitive assessment
Study: NCT00621023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, Arsenic Trioxide and Ascorbic Acid
Description: Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
Study: NCT03440112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin (Not used as of 4/2020)
Description: Clarithromycin (generic) capsule 250mg each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Not used as of 4/2020)
Description: Lactose in a gel capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal flumazenil (Added 4/2020)
Description: Transdermal flumazenil 24mg/mL
Study: NCT00712049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic Acid
Description: daily dose starting with 500 mg, up to 2000mg
Study: NCT01153503

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn
Study: NCT03440112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Added 4/2020)
Description: Transdermal placebo
Study: NCT00676052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 12.5mcg
Description: Once daily via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 25mcg
Description: once daily via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 50mcg
Description: Once daily via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 100mcg
Description: Once daily via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705 200mcg
Description: Once daily via dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily via dry powder imhaler
Study: NCT03600428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Description: 1 dose, 0.2 mL, intranasal administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Description: 1 dose, 0.5 mL, intramuscular administration
Study: NCT03004456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
Study: NCT03429205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No external heating used during surgery
Description: Deviation from external heating for all surgery standard

Intervention type: OTHER
Group type: OTHER
Intervention: External heating blanket used during surgery
Description: Standard external heating plan used in all surgery types
Study: NCT00661219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
Study: NCT04050748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles tendon repair
Description: Patients will be undergoing achilles tendon repair
Study: NCT02361684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended CBT treatment
Description: Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
Study: NCT04050748

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Achilles tendon repair
Description: Patients will be undergoing achilles tendon repair
Study: NCT03751787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranial osteopathy
Description: two sessions at three weeks intervals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: comfort massage
Description: manipulation, comfort massage, standardized and not affecting the skull
Study: NCT00267319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Study: NCT03818932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: Traditionally used narcotic pain protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT01964456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measure of the heart rate
Study: NCT04138966

Intervention type: DEVICE
Intervention: Nol-Index
Description: Multiparametric monitor that studies that establishes an index as a surrogate to nociception
Study: NCT00673842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator + Usual Care
Description: Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual post-MI care
Study: NCT00829452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg capsule
Description: 1 x 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace® 10 mg capsule
Description: 1 x 10 mg